Novartis gene therapy would be cost effective up to $900000 U.S. group

Novartis gene therapy would be cost effective up to $900,000: U.S. group

An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medica...

Original Article: Novartis gene therapy would be cost effective up to $900,000: U.S. group

More From BioPortfolio on "Novartis gene therapy would be cost effective up to $900,000: U.S. group"